Veronica V. Urdaneta, MD, MPH

Global Clinical Safety Lead COVID-19 Program
Moderna, Inc.

Poster(s):

• (102) Evaluation of postmenopausal hemorrhage following Moderna COVID-19 vaccines: results from surveillance data analysis and interim results from a US claims database cohort study
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (330) A Comparison of Natural Language Processing (NLP) vs Clinician Review for Identification of Myocarditis Cases Following Vaccination with mRNA-1273
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (337) Defining a Post-vaccine Myocarditis Cohort by Applying CDC Case Definition to Structured EHR and Claims Data as a Proxy for Case Adjudication
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (367) VAC4EU study to identify risk factors and characterize the clinical course of myocarditis/pericarditis following mRNA-1273 vaccination in four European countries: first descriptive analyses
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST